男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Vaccine from BioNTech, Fosun to enter phase 2 trials

By SHI JING in Shanghai | chinadaily.com.cn | Updated: 2020-11-26 15:42
Share
Share - WeChat

German biotechnology company BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co Ltd jointly announced on Wednesday that their lead mRND COVID-19 vaccine candidate BNT162b2 will be evaluated in a phase 2 clinical trial.

The phase 2 clinical trial will be carried out in Taizhou and Lianshui of East China's Jiangsu province. Jiangsu Provincial Center for Disease and Prevention will be responsible for the trial.

The online recruitment of volunteers will commence with the recruitment of 960 healthy participants, aged between 18 and 85, to assess the safety and immunogenicity of the vaccine candidate and to support future biologic license applications in China.

In the ongoing phase 3 clinical study of the vaccine, BNT162b2 met all primary efficacy endpoints, with an efficacy rate of 95 percent in preventing symptomatic COVID-19 infections. Sufficient safety data was collected to support the submission of an emergency use authorization to the US Food and Drug Administration on Nov 20. In addition, BNT162b2 is currently under regulatory review by regulatory authorities in Europe, the United Kingdom and Canada.

According to Ugur Sahin, CEO and co-founder of BioNTech, the clinical trial research carried out in China is an important part of the global research and development of the company's COVID-19 vaccine and marks an important step in bringing this vaccine to the people of China.

On March 13, Fosun Pharma became the strategic partner of BioNTech in China, jointly developing and commercializing vaccine products for COVID-19 based on its proprietary mRNA technology platform in China. Apart from discussing the research and development plans with partners and completing clinical trials in China, Fosun Pharma has also designed and completed animal challenge trials of selected mRNA vaccines, including BNT162b2, in collaboration with Chinese research institutes, and shared outcomes with partners in a timely manner.

Hui Aimin, chief medical officer of Fosun Pharma, said that the COVID-19 pandemic proves once again that global cooperation is needed to control infectious diseases.

"As an important part of global research and development, the phase two clinical study with BNT162b2 in China will not only provide key data for the launch of the vaccine in China, but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world," he said.

Fosun Pharma announced on Wednesday a private placement plan in the A-share market. The financing value is estimated at around 4.98 billion yuan ($758.25 million), which will be mainly used for the development, commercial license and introduction permits of innovative drugs, including the development of the highly anticipated mRNA COVID-19 vaccine.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 大丰市| 宁远县| 隆安县| 延安市| 永宁县| 丽江市| 城市| 高陵县| 东乌珠穆沁旗| 犍为县| 浦县| 蓝田县| 淅川县| 永昌县| 斗六市| 平邑县| 沙田区| 木兰县| 赣州市| 嵊泗县| 永定县| 潍坊市| 阳信县| 枞阳县| 哈尔滨市| 岫岩| 巴彦县| 板桥市| 甘泉县| 马山县| 灌南县| 涞水县| 卓资县| 射阳县| 水富县| 许昌市| 延寿县| 思南县| 宝兴县| 信阳市| 古交市|